What Elantan LA25 Treats: Main Uses and Benefits

Elantan LA25 (isosorbide mononitrate) is used for the long-term management of angina pectoris, which is chest pain or discomfort resulting from coronary artery disease. This extended-release formulation is intended to assist in the prevention of angina attacks by helping to maintain appropriate blood flow to the heart.

The clinical use focuses on providing symptom relief by working to reduce the frequency of angina episodes.

The recognized therapeutic domains for this medicine include the prophylaxis of angina pectoris. It may also be considered for use in the overall management plan for heart failure, in combination with other treatments.

“This medication is used to prevent angina symptoms (chest pain).”

---

Quick Fact: Relief for Angina Chest Pain

Elantan LA 25 (Isosorbide Mononitrate) eligibility is strictly defined by regulatory bodies, primarily excluding individuals with certain severe health conditions and specific co-medication use.

Populations for Whom Use is Prohibited (Contraindicated)

Category	Official Exclusion Status
Cardiovascular	Severe hypotension (systolic BP leq 90 mmHg), acute circulatory failure (shock/collapse), acute myocardial infarction with low filling pressure, and specific heart conditions (e.g., HOCM, cardiac tamponade).
Co-Medications	Patients using Phosphodiesterase type-5 (PDE-5) inhibitors (e.g., sildenafil) or the soluble guanylate cyclase stimulator riociguat.
Other Conditions	Severe anaemia, closed-angle glaucoma, and hypersensitivity to nitrates or excipients.

Restricted and Age-Related Eligibility

Age-Related Eligibility: This medicine is intended for adults. The safety and efficacy has yet to be established in children, making its use generally not suitable for the paediatric population. No routine dosage adjustment is suggested for the elderly.

Condition-Specific Caution: Use requires special caution in patients with severe liver disease, severe renal disease, hypothyroidism, hypothermia, or malnutrition.

Pregnancy/Lactation: Safety has not been established. Use is only permissible if the physician determines the possible benefits of treatment outweigh the possible hazards.

️ Interactions with other medicines and products

This section describes the officially documented interaction patterns for Elantan LA25 (Isosorbide Mononitrate) as outlined in government regulatory prescribing information, focusing on substances that modify the drug's effects or alter drug exposure.

Formally Contraindicated Combinations

Regulatory documents specify that Elantan LA25 must not be co-administered with certain medications due to a severe interaction risk:

• Phosphodiesterase Type 5 (PDE5) Inhibitors: These include drugs like Sildenafil, Tadalafil, and Vardenafil. Co-administration is contraindicated as it severely potentiates the blood pressure-lowering effect (hypotension), leading to the risk of cardiovascular collapse.
• Riociguat: This Soluble Guanylate Cyclase Stimulator is also contraindicated for concurrent use as it can result in significant hypotension.

Other Documented Pharmacodynamic Interactions

• Other Blood Pressure Lowering Medicines: Concurrent use with agents such as beta-blockers, calcium channel blockers, vasodilators, tricyclic antidepressants, and neuroleptics may potentiate the overall hypotensive effect of Elantan LA25.
• Alcohol (Ethanol): Consumption of alcohol may lead to an additive hypotensive effect, increasing the risk of dizziness or faintness.

Exposure-Altering Interactions

• Dihydroergotamine: Co-administration may increase the blood level of Dihydroergotamine, potentially enhancing its effects.

There are no mandatory timing separation rules documented in the regulatory label for interacting medicines. The official information also notes that food does not have a significant impact on Elantan LA25 absorption.

The mechanism of Elantan LA25 is centered on the single active ingredient, Isosorbide Mononitrate (ISMN), which acts as a prodrug to modulate vascular tone by initiating a specific molecular cascade.

Molecular Action and Vascular Smooth Muscle Relaxation

ISMN is converted into Nitric Oxide (NO), which then activates the enzyme soluble guanylyl cyclase (sGC), leading to a surge in the second messenger cGMP. This cascade triggers the relaxation of vascular smooth muscle cells, which is the initial cellular step leading to subsequent hemodynamic changes.

Reducing Cardiac Workload (Preload Modulation)

The resultant smooth muscle relaxation preferentially affects the venous capacitance vessels, causing the peripheral pooling of blood. This action lowers the volume of blood returning to the heart, which is known as decreasing the cardiac preload. The reduction in preload constitutes a major pathway by which the mechanism decreases myocardial oxygen demand.

⬆️ Improving Oxygen Supply (Coronary Flow)

Concurrently, the mechanism also involves the dilation of the coronary arteries and collateral channels. This enhances the distribution of blood flow and the subsequent delivery of oxygen toward the subendocardial layers of the heart muscle. This effect establishes conditions that influence the balance between myocardial oxygen supply and demand.

Administration Instructions

Elantan LA25 is a prolonged-release hard capsule containing 25 mg of isosorbide mononitrate, and it is strictly for oral administration. The medicine is prescribed for use in a once-daily schedule, which is essential to create a daily nitrate-free interval to mitigate the risk of pharmacological tolerance and maintain long-term efficacy.

Dosing and Timing

The standard adult starting dose for the prophylaxis of angina pectoris is typically 25 mg taken once a day. The dose may be increased, with a common maximum maintenance dose often being 50 mg (two 25 mg capsules) once daily, according to patient requirement. The daily dose must be taken in the morning with liquid, such as water. It may be taken with or without food.

Administration Prerequisites

To ensure the controlled, long-acting function of the capsule is preserved, the prolonged-release capsule must be swallowed whole and must not be crushed or chewed. The medicine is intended solely for prophylactic use to prevent anginal episodes; it is not to be used for the immediate relief of an acute angina attack. The duration of therapy is intended to be long-term, and treatment should not be stopped suddenly; the dosage and frequency must be tapered gradually.

Population Considerations

Information indicates that no routine dosage adjustment is required for older adults. However, the safety and efficacy of Elantan LA25 have not been established in children, meaning its use is not intended for pediatric patients.

Research Evidence / Overview of Studies for Elantan LA25

---

Evidence for the Prevention of Chronic Stable Angina Pectoris

Clinical research for long-acting isosorbide mononitrate (ISMN) formulations, like Elantan LA25, primarily involves Randomized Controlled Trials (RCTs) and systematic reviews comparing the medication against placebo or established comparators. Studies were primarily conducted in patients with stable health, exploring its role in the chronic management of angina.

Researchers monitored and measured changes that occurred during the study period. These outcomes were related to functional measures, specifically tracking how long a patient could safely exercise before the onset of symptoms. Studies also monitored the frequency of reported angina episodes and the use of acute-relief medication, with research exploring how symptoms change over time.

---

Exploratory Research in Other Cardiovascular Contexts

Beyond its primary focus on angina, research has also examined the drug in other, more specialized scenarios. Studies have explored its use in systolic hypertension (a type of high blood pressure), particularly in older adults. Research reports measurements of vascular outcomes observed in these study populations.

In a different area, initial research has been conducted to study the medicine in patients who have recently experienced a lacunar ischemic stroke. Findings for these conditions are still emerging and contribute to the broader evidence landscape but are not yet sufficient to determine its established use in clinical guidelines.

---

Research Gaps and Remaining Uncertainties

While the research provides considerable insight into the study of this medication for chronic stable angina, several areas remain limited or unclear:

• Major Clinical Outcomes: There is limited information for long-term outcomes such as preventing major cardiovascular events (e.g., heart attack or stroke) or research on survival rates.
• Specialized Subgroups: Data for certain groups, particularly the pediatric population, remain insufficient.

Key Studies & References

1. Isosorbide Mononitrate. [StatPearls Comprehensive Review of Pharmacology and Clinical Use]
2. Chronic coronary syndromes: NICE Guideline NG216

Common questions about Elantan LA25 (FAQ)

---

Q: How is Elantan LA25 different from short-acting versions of the same medicine?

A: Official product information describes Elantan LA25 as a prolonged-release formulation, meaning the active substance is released slowly over time. This design is intended to provide sustained action over an extended duration, as described in product studies. Because of its sustained action, this medicine is used strictly for prevention of anginal episodes, not for the immediate relief of an acute attack like short-acting nitrates.

Q: Can Elantan LA25 cause headaches when first starting the treatment?

A: Yes, headache is a very common side effect reported in official documents, often occurring when first starting treatment. This occurrence is sometimes associated with the drug's intended action of widening blood vessels. For many patients, regulatory sources indicate this initial headache typically lessens or resolves after the first few days of use.

Q: Is Elantan LA25 similar to nitroglycerin?

A: According to official regulatory classifications, the active ingredient in Elantan LA25 belongs to the same class of medicines as nitroglycerin (often called organic nitrates). Both of these compounds work in the body by acting as a Nitric Oxide donor, which helps to relax and widen blood vessels.

Q: What are the most commonly reported less serious side effects of Elantan LA25?

A: The most frequently reported side effect in official documents is headache. Other common effects, which affect less than 1 in 10 people, include feelings of dizziness, somnolence (sleepiness), or general weakness. The regulatory safety profile organizes all known effects by how often they are reported.

Q: What types of heart conditions is Elantan LA25 typically used to manage?

A: The official, primary purpose of this medicine is the prophylaxis (prevention) of chronic stable angina pectoris. Regulatory labels in some regions may also recognize its use in the management of other circulatory issues, such as certain forms of congestive heart failure.

Q: Does Elantan LA25 affect kidney function?

A: Official prescribing information advises that the medicine should be used with caution in patients diagnosed with severe kidney disease. This indicates that the effect on kidney function is a required consideration in certain populations, but the documents do not describe the specific mechanism or impact in the general population.

Q: Can taking Elantan LA25 impact sleep patterns?

A: Yes, official safety information lists somnolence (sleepiness) as a common side effect, which relates to the body's wakefulness cycle. However, regulatory documents do not explicitly list insomnia (inability to sleep) as a commonly reported effect.

Q: What are the ingredients in the Elantan LA25 capsule/tablet shell?

A: The capsule contains the active ingredient, isosorbide mononitrate, along with several inactive ingredients, or excipients. Regulatory documents confirm these include lactose monohydrate, sucrose, corn starch, and gelatin. The complete list of ingredients is provided in the official patient information leaflet.

Q: Is 'angina pectoris' the only condition Elantan LA25 is approved for?

A: While the prevention of angina pectoris is the most widely recognized use in official documentation, the scope of approved indications can vary by region. Regulatory labels in certain countries may also list the treatment of heart failure.

Q: Does Elantan LA25 have a risk of dependence or withdrawal?

A: Official prescribing information indicates that treatment should be tapered gradually and not stopped suddenly. Regulatory information notes that physical dependence has been reported in workers with high-dose exposure, although the relevance of this observation for typical clinical use is not confirmed.

Q: Is a low blood pressure reading a normal expectation when starting Elantan LA25?

A: The mechanism of this drug is to widen blood vessels, which naturally leads to a lowering of blood pressure. Official safety information lists related symptoms like dizziness and lightheadedness as common, especially at the start of therapy. This effect is a result of the medicine's action; however, any concerning blood pressure changes require consultation with a healthcare provider.

Q: What is the general consensus on using Elantan LA25 with other heart medicines?

A: Regulatory documents indicate that using this medicine concurrently with other blood pressure-lowering agents, such as beta-blockers or calcium channel blockers, may lead to a greater-than-expected reduction in blood pressure (potentiated hypotensive effect). For this reason, official labels reflect that combining these medications requires careful medical oversight.

Q: What should be done if a dose is missed?

A: Official patient information indicates that if a dose is remembered, it may be taken immediately. However, if it is close to the next scheduled dose, the forgotten dose is typically skipped, and the regular schedule continues. Official guidance strongly states that a double dose must not be taken to compensate for a missed dose.

How to Store and Dispose of Elantan LA25

The storage and disposal of Elantan LA25 (isosorbide mononitrate) must adhere strictly to officially documented regulatory requirements to ensure product stability and safety.

Storage Requirements

Condition	Requirement
Maximum Temperature	Do not store above 30 C
Child Safety	Keep out of the sight and reach of children
Shelf-Life	The documented shelf-life is 5 years

️ Disposal Rules

Official regulations prohibit discarding this medicine via wastewater or household waste. The product must not be used after the printed expiry date. For proper disposal of unused or expired Elantan LA25, individuals are directed to consult a pharmacist for guidance on authorized take-back or disposal programs.